|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM364387181 |
| 003 |
DE-627 |
| 005 |
20240207232111.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202310078
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1283.xml
|
| 035 |
|
|
|a (DE-627)NLM364387181
|
| 035 |
|
|
|a (NLM)37947048
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhu, Chunyan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Injectable Supramolecular Hydrogels for In Situ Programming of Car-T Cells toward Solid Tumor Immunotherapy
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.02.2024
|
| 500 |
|
|
|a Date Revised 06.02.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Chimeric antigen receptor (CAR)-T cell immunotherapy is approved in the treatment of hematological malignancies, but remains far from satisfactory in solid tumor treatment due to inadequate intra-tumor CAR-T cell infiltration. Herein, an injectable supramolecular hydrogel system, based on self-assembly between cationic polymer mPEG-PCL-PEI (PPP) conjugated with T cell targeting anti-CD3e f(ab')2 fragment and α-cyclodextrin (α-CD), is designed to load plasmid CAR (pCAR) with a T cell specific CD2 promoter, which successfully achieves in situ fabrication and effective accumulation of CAR-T cells at the tumor site in humanized mice models. More importantly, due to this tumor microenvironment reprogramming, secretion of cellular inflammatory cytokines (interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ)) or tumor killer protein granzyme B is significantly promoted, which reverses the immunosuppressive microenvironment and significantly enhances the intra-tumor CAR-T cells and cytotoxic T cells infiltration. To the best of the current knowledge, this is a pioneer report of using injectable supramolecular hydrogel for in situ reprogramming CAR-T cells, which might be beneficial for solid tumor CAR-T immunotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a CAR-T cells
|
| 650 |
|
4 |
|a immunotherapy
|
| 650 |
|
4 |
|a solid tumors
|
| 650 |
|
4 |
|a supramolecular hydrogel
|
| 650 |
|
4 |
|a sustained-release system
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Hydrogels
|2 NLM
|
| 700 |
1 |
|
|a Ke, Lingjie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ao, Xiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Hongwei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xin, Huhu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Xiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Loh, Xian-Jun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Zibiao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lyu, Haiyan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Qi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Dandan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ping, Yuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Caisheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Yun-Long
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 5 vom: 01. Feb., Seite e2310078
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:5
|g day:01
|g month:02
|g pages:e2310078
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202310078
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 5
|b 01
|c 02
|h e2310078
|